Age: 62.0
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: COVID-19 immunisation, Off label use, Suspected COVID-19
Clinical narrative: SUSPECTED COVID-19 INFECTION; REVACCINATION WITH DIFFERENT COVID-19 VACCINE; OFF LABEL DOSING FREQUENCY; This spontaneous report received from a patient via other manufacturer (Pfizer) concerned a 62 year old male. The patient's height, and weight were not reported. The patient's concurrent conditions included: allergy. The patient was previously treated with Pfizer BionTech (tozinameran) (Dose number in series 1) (form of admin, route of admin were not reported, batch number:1805020 expiry: UNKNOWN) dose was not reported, administered on 18-MAR-2021 for covid-19 prophylaxis. It was unknown whether patient had any adverse events following vaccination with Pfizer BionTech (tozinameran) (Dose number in series 1). The patient was previously treated with covid-19 vaccine ad26. cov2. s (Dose number in series 2) (suspension for injection, route of admin not reported, batch number: 1805020 expiry: UNKNOWN) dose was not reported, 1 total administered on 13-MAY-2021 for covid-19 prophylaxis. It was unknown whether patient had any adverse events following vaccination with covid-19 vaccine ad26. cov2. s (Dose number in series 2). The patient received covid-19 vaccine ad26.cov2.s (Dose number in series 3) (suspension for injection, route of admin not reported, batch number: 1822809 expiry: UNKNOWN) dose was not reported, 1 total administered on 23-OCT-2021 for covid-19 prophylaxis which was associated with off label dosing frequency. The product was associated with Off label use (Dose number in series 3). Age at time of vaccination 62 years old. No concomitant medications were reported.  The patient also received non-company suspect vaccine Moderna (elasomeran) (Dose number in series 4) (form of admin, route of admin were not reported, batch number: 016J21-2A expiry: UNKNOWN) dose was not reported, administered on 01-APR-2022 for covid-19 prophylaxis. It was unknown whether patient had any adverse events following vaccination with Moderna (elasomeran) (Dose number in series 4). The patient additionaly received non-company suspect vaccine Moderna (elasomeran) (Dose number in series 5) (form of admin, route of admin were not reported, batch number: AS7162B expiry: UNKNOWN) dose was not reported, administered on 22-SEP-2022 for covid-19 prophylaxis which was revaccination with different covid-19 vaccine (Dose number in series 5).  On an unspecified date in 2023, the patient experienced suspected covid-19 infection (Dose number in series 5) for which the patient was treated with non-company suspect drug Paxlovid (nirmatrelvir/ritonavir) (form of admin, route of admin, batch number and expiry date were not reported) dose and frequency were not reported from 05-APR-2023 to 09-APR-2023 for covid-19 treatment.  On 15-APR-2023, the patient experienced rebound covid after paxlovid (Dose number in series 5). The action taken with covid-19 vaccine ad26.cov2.s, elasomeran, and elasomeran was not applicable; and action taken with nirmatrelvir/ritonavir was not reported. The outcome of the suspected covid-19 infection, off label dosing frequency and revaccination with different covid-19 vaccine was not reported. This report was non-serious.